Heterocyclic compound, composition and use thereof

Abstract

The invention provides a heterocyclic compound as well as a composition and application thereof. Specifically provided is a compound represented by formula II or a pharmaceutically acceptable salt thereof. The compound has one or more of the following advantages: the structure is novel, IKZF2 can be efficiently and highly selectively degraded, the functions of T cells are inhibited and regulated, the compound is applied to treatment of tumors or diseases, and the compound has huge clinical development value.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480061168.5 (22) Application Date 2024.09.27 (66) Domestic Priority Data 202311275609.5 2023.09.28 CN (85) PCT International Application Entering National Phase Date 2026.03.24 (86) PCT International Application Application Data PCT / CN2024 / 121866 2024.09.27 (87) PCT International Application Publication Data WO2025 / 067466 ZH 2025.04.03 (71) Applicant Hangzhou Duoyu Biotechnology Co., Ltd. Address 311100 Room 401, Building 3, No. 110 Liuze Street, Yuhang District, Hangzhou City, Zhejiang Province (72) Inventors: Xiang Shaoyun, Wu Lei, Liu Yuxin, Yang Meng, Zhang Bing, Chen Yufeng, Yang Rui (74) Patent Agency: Shanghai Bixing Law Firm, 31283 Patent Attorney: Xu Jiechao (51) Int.Cl. C07D 401 / 14 (2006.01) A61K 31 / 454 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: A Heterocyclic Compound, Composition Thereof and Applications (57) Abstract: This invention provides a heterocyclic compound, its composition and applications. Specifically, it provides a compound as shown in Formula II or a pharmaceutically acceptable salt thereof. The compounds of this invention have one or more of the following advantages: novel structure, efficient and selective degradation of IKZF2, inhibition of regulatory T cell function, application in the treatment of tumors or diseases and great clinical development value. CN 121986094 A 2026.05.05 CN 1 21 98 60 94 A